|
| | |
|
Am J Psychiatry 1994; 151:1105-1113
Copyright © 1994 by American Psychiatric Association
Inflammatory mechanisms in Alzheimer's disease: implications for therapy
PS Aisen and KL Davis
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029.
OBJECTIVE: The purpose of this article is to review evidence that
inflammatory and immune mechanisms are important in the pathophysiology of
Alzheimer's disease and to suggest new treatment strategies. METHOD: The
authors review the English-language literature of the last 10 years
pertaining to the pathophysiology of Alzheimer's disease. RESULTS: There is
ample evidence supporting the hypothesis that inflammatory and immune
mechanisms are involved in tissue destruction in Alzheimer's disease. Acute
phase proteins are elevated in the serum and are deposited in amyloid
plaques, activated microglial cells that stain for inflammatory cytokines
accumulate around senile plaques, and complement components including the
membrane attack complex are present around dystrophic neurites and
neurofibrillary tangles. CONCLUSIONS: Clinical trials of
anti-inflammatory/immunosuppressive drugs are necessary to determine
whether alteration of these inflammatory mechanisms can slow the
progression of Alzheimer's disease.
This article has been cited by other articles:
|
|
|
|
 
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
J. M. Seddon, S. George, B. Rosner, and N. Rifai
Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers
Arch Ophthalmol,
June 1, 2005;
123(6):
774 - 782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Grainger, J. Reckless, and E. McKilligin
Apolipoprotein E Modulates Clearance of Apoptotic Bodies In Vitro and In Vivo, Resulting in a Systemic Proinflammatory State in Apolipoprotein E-Deficient Mice
J. Immunol.,
November 15, 2004;
173(10):
6366 - 6375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Sagi, S. Weggen, J. Eriksen, T. E. Golde, and E. H. Koo
The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of {kappa}B Kinase, and NF{kappa}B, Do Not Reduce Amyloid {beta}42 Production
J. Biol. Chem.,
August 22, 2003;
278(34):
31825 - 31830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Landi, M. Cesari, G. Onder, A. Russo, S. Torre, and R. Bernabei
Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients
Am J Geriatr Psychiatry,
April 1, 2003;
11(2):
179 - 185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker
Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence
Epidemiol. Rev.,
December 1, 2002;
24(2):
248 - 268.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Suh and F. Checler
Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease
Pharmacol. Rev.,
September 1, 2002;
54(3):
469 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. TUCKER and G. H. SACK JR
Expression of serum amyloid A genes in mouse brain: unprecedented response to inflammatory mediators
FASEB J,
October 1, 2001;
15(12):
2241 - 2246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Matsuoka, M. Picciano, B. Malester, J. LaFrancois, C. Zehr, J. M. Daeschner, J. A. Olschowka, M. I. Fonseca, M. K. O'Banion, A. J. Tenner, et al.
Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer's Disease
Am. J. Pathol.,
April 1, 2001;
158(4):
1345 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Heneka, T. Klockgether, and D. L. Feinstein
Peroxisome Proliferator-Activated Receptor-gamma Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell Death In Vivo
J. Neurosci.,
September 15, 2000;
20(18):
6862 - 6867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Engelhardt, W.-D. Le, L. Siklos, I. Obal, K. Boda, and S. H. Appel
Stereotaxic Injection of IgG From Patients With Alzheimer Disease Initiates Injury of Cholinergic Neurons of the Basal Forebrain
Arch Neurol,
May 1, 2000;
57(5):
681 - 686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Masaki, K. G. Losonczy, G. Izmirlian, D. J. Foley, G. W. Ross, H. Petrovitch, R. Havlik, and L. R. White
Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
Neurology,
March 28, 2000;
54(6):
1265 - 1272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Naslund, V. Haroutunian, R. Mohs, K. L. Davis, P. Davies, P. Greengard, and J. D. Buxbaum
Correlation Between Elevated Levels of Amyloid {beta}-Peptide in the Brain and Cognitive Decline
JAMA,
March 22, 2000;
283(12):
1571 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Aisen, K. L. Davis, J. D. Berg, K. Schafer, K. Campbell, R. G. Thomas, M. F. Weiner, M. R. Farlow, M. Sano, M. Grundman, et al.
A randomized controlled trial of prednisone in Alzheimer's disease
Neurology,
February 8, 2000;
54(3):
588 - 588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Shua-Haim and J. S. Ross
Current and the near future medications for Alzheimer's disease: What can we expect from them?
American Journal of Alzheimer's Disease and Other Dementias,
September 1, 1999;
14(5):
294 - 307.
[PDF]
|
|
|
|
|
|
|
O. Felician and T. A. Sandson
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
J Neuropsychiatry Clin Neurosci,
February 1, 1999;
11(1):
19 - 31.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. M. Gabriel, D. B. Marin, P. S. Aisen, M. Lantz, L. D. Altstiel, K. L. Davis, and R. C. Mohs
Association of Elevated {alpha}1-Antichymotrypsin With Cognitive Impairment in a Prospective Study of the Very Old
Am J Psychiatry,
May 1, 1998;
155(5):
698 - 700.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Kaltschmidt, M. Uherek, B. Volk, P. A. Baeuerle, and C. Kaltschmidt
Transcription factor NF-kappa B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease
PNAS,
March 18, 1997;
94(6):
2642 - 2647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Backstrom, G. P. Lim, M. J. Cullen, and Z. A. Tokes
Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-beta Peptide (1-40)
J. Neurosci.,
December 15, 1996;
16(24):
7910 - 7919.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1994
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
